Commercialization support following the out-licensing of an anti-α9 integrin antibody
First written in FY2016. 3 of 6 entries say "Restated". Latest entry: FY2021-Q1.
No other company in this theme has enough history to compare yet.
- FY2021-Q1DroppedAnnual report
「Regarding development of the anti-human α9 integrin antibody (development code: GND-001) in the biologics business, the company and its joint research partner, KAKEN PHARMACEUTICAL CO.,LTD., reassessed and discussed the antibody's commercial potential. They concluded that further research and development would be necessary to commercialize it as a prescription pharmaceutical and formally agreed to terminate the license agreement.」
The company formally agreed to terminate the license agreement with KAKEN PHARMACEUTICAL CO.,LTD. for the anti-human α9 integrin antibody. - FY2020DroppedAnnual report
「Regarding the license agreement concerning the development and manufacturing and commercialization rights for the anti-human α9 integrin antibody entered into with KAKEN PHARMACEUTICAL CO.,LTD. on 29 June 2007, the two companies reassessed and discussed the antibody's commercial potential. They concluded that further research and development would be necessary to commercialize the antibody as a prescription pharmaceutical, and the board of directors resolved at its meeting on 25 May 2020 to terminate the license agreement.」
Support for commercialization following the out-licensing to KAKEN PHARMACEUTICAL CO.,LTD. ended with the resolution to terminate the license agreement. - FY2019RestatedAnnual report
「Although this development program has already been out-licensed to KAKEN PHARMACEUTICAL CO.,LTD., the company continues joint research with KAKEN PHARMACEUTICAL CO.,LTD., including research into manufacturing processes for large-scale production and the narrowing down of optimal target diseases for commercialization.」
The company has reconfirmed its policy of continuing to support large-scale manufacturing methods and the narrowing down of target diseases for the out-licensed anti-α9 integrin antibody. - FY2018RestatedAnnual report
「Although this development program has already been out-licensed to KAKEN PHARMACEUTICAL CO.,LTD., the company continues joint research with KAKEN PHARMACEUTICAL CO.,LTD., including research into manufacturing processes for large-scale production and the narrowing down of optimal target diseases for commercialization.」
The company continues to support large-scale manufacturing methods and the narrowing down of target diseases for the out-licensed anti-α9 integrin antibody. - FY2017RestatedAnnual report
「Although this development program has already been out-licensed to KAKEN PHARMACEUTICAL CO.,LTD., the company continues joint research with KAKEN PHARMACEUTICAL CO.,LTD., including research into manufacturing processes for large-scale production and the narrowing down of optimal target diseases for commercialization.」
The company continues to support large-scale manufacturing methods and the narrowing down of target diseases for the out-licensed anti-α9 integrin antibody. - FY2016First statedAnnual report
「The company continues to conduct joint research with the company, including research into manufacturing processes for large-scale production and the narrowing down of optimal target diseases for commercialization.」
GND-001 has already been transferred to KAKEN PHARMACEUTICAL CO.,LTD. under an exclusive development, manufacturing and commercialization license. The company supports development of large-scale manufacturing methods, narrowing down target diseases and partnerships for global expansion, in a structure that generates milestone payments and royalties.